{"id":8945,"date":"2018-04-24T11:41:49","date_gmt":"2018-04-24T09:41:49","guid":{"rendered":"https:\/\/www.satt.fr\/maladies-rares-signature-dun-partenariat-entre-ligbmc-satt-conectus-societe-lysogene\/"},"modified":"2018-04-24T11:41:49","modified_gmt":"2018-04-24T09:41:49","slug":"maladies-rares-signature-dun-partenariat-entre-ligbmc-satt-conectus-societe-lysogene","status":"publish","type":"post","link":"https:\/\/www.satt.fr\/en\/maladies-rares-signature-dun-partenariat-entre-ligbmc-satt-conectus-societe-lysogene\/","title":{"rendered":"Maladies rares : signature d&#8217;un partenariat entre l&#8217;IGBMC, la SATT Conectus et la soci\u00e9t\u00e9 Lysogene"},"content":{"rendered":"<p><strong>Lysogene<\/strong>, soci\u00e9t\u00e9 biopharmaceutique pionni\u00e8re et sp\u00e9cialis\u00e9e dans la th\u00e9rapie g\u00e9nique ciblant les maladies rares du syst\u00e8me nerveux central, a sign\u00e9 un accord de partenariat avec le Dr. Herv\u00e9 Moine, chercheur au sein de l\u2019\u00e9quipe du\u00a0<strong>Pr. Jamel Chelly \u00e0 l\u2019IGBMC de Illkirch<\/strong>\u00a0(CNRS, Inserm et Universit\u00e9 de Strasbourg) et la\u00a0<strong>SATT Conectus<\/strong>.<\/p>\n<p>Ce partenariat a \u00e9t\u00e9 notablement facilit\u00e9 par\u00a0<strong>La Fondation Maladies Rares<\/strong>, via son Club POC (Proof Of Concept) de la valorisation de la recherche et gr\u00e2ce \u00e0 sa connaissance des acteurs acad\u00e9miques et industriels du domaine.<\/p>\n<h3><strong>L\u2019accord porte sur le d\u00e9veloppement d\u2019un produit de th\u00e9rapie g\u00e9nique destin\u00e9 au traitement des patients atteints du syndrome de l\u2019X Fragile.\u00a0<\/strong>Le syndrome de l\u2019X Fragile touche approximativement 1 naissance sur 4 \u00e0 5 000 gar\u00e7ons et 1 naissance sur 8 000 filles, soit environ 110 000 patients en Europe. Il est aujourd\u2019hui la\u00a0<strong>premi\u00e8re cause h\u00e9r\u00e9ditaire de d\u00e9ficience intellectuelle<\/strong>\u00a0ainsi que la premi\u00e8re cause connue de troubles du spectre\u00a0<strong>autistique<\/strong>, et il n\u2019a pas encore de traitement curatif.<\/h3>\n<p>&nbsp;<\/p>\n<p>Ce partenariat sera mis en \u0153uvre sur un format original de\u00a0<strong>co-conception<\/strong>. Impuls\u00e9 par la SATT Conectus, ce dispositif propose d\u2019associer tr\u00e8s t\u00f4t une entreprise au d\u00e9veloppement d\u2019un projet innovant port\u00e9 par un chercheur et de combiner le soutien financier de Conectus avec l\u2019expertise industrielle et de d\u00e9veloppement de la soci\u00e9t\u00e9. Si le projet aboutit positivement, l\u2019entreprise b\u00e9n\u00e9ficie d\u2019une option sur licence, lui garantissant un acc\u00e8s prioritaire \u00e0 la technologie d\u00e9velopp\u00e9e.<\/p>\n<p>\u00ab\u00a0<em>La SATT Conectus est tr\u00e8s motiv\u00e9e pour s\u2019engager sur ce projet prometteur. Notre investissement de plus de 390 k\u20ac dans le projet en question (projet GETEX), et la propri\u00e9t\u00e9 intellectuelle associ\u00e9e, doivent permettre de valider la pertinence de l\u2019approche de th\u00e9rapie g\u00e9nique propos\u00e9e et d\u2019en cadrer au mieux l\u2019ad\u00e9quation aux besoins du march\u00e9. Nous sommes \u00e9galement heureux de nous associer au Dr. Herv\u00e9 Moine et \u00e0 Lysogene, partenaire-cl\u00e9 choisi apr\u00e8s un processus de s\u00e9lection rigoureux, notamment pour sa ma\u00eetrise de l\u2019approche de th\u00e9rapie g\u00e9nique du syst\u00e8me nerveux central\u00a0<\/em>\u00bb commente Nicolas Carboni, Pr\u00e9sident de la SATT Conectus.<\/p>\n<h3><a href=\"http:\/\/www.conectus.fr\/sites\/default\/files\/presse\/communiques\/lysogene_cp_fr_fragile_x_accord_de_partenariat_fr_prefinal_v2.pdf\"><strong>D\u00e9couvrir le communiqu\u00e9 de presse dans son int\u00e9gralit\u00e9<\/strong><\/a><\/h3>\n","protected":false},"excerpt":{"rendered":"<p>Lysogene, soci\u00e9t\u00e9 biopharmaceutique pionni\u00e8re et sp\u00e9cialis\u00e9e dans la th\u00e9rapie g\u00e9nique ciblant les maladies rares du syst\u00e8me nerveux central, a sign\u00e9 un accord de partenariat avec le Dr. Herv\u00e9 Moine, chercheur au sein de l\u2019\u00e9quipe du\u00a0Pr. Jamel Chelly \u00e0 l\u2019IGBMC de Illkirch\u00a0(CNRS, Inserm et Universit\u00e9 de Strasbourg) et la\u00a0SATT Conectus. Ce partenariat a \u00e9t\u00e9 notablement facilit\u00e9 [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":8944,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[567,568],"tags":[],"class_list":["post-8945","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-en","category-successstories-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Maladies rares : signature d&#039;un partenariat entre l&#039;IGBMC, la SATT Conectus et la soci\u00e9t\u00e9 Lysogene - R\u00e9seau SATT<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.satt.fr\/en\/maladies-rares-signature-dun-partenariat-entre-ligbmc-satt-conectus-societe-lysogene\/\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"France MANDRY\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.satt.fr\/en\/maladies-rares-signature-dun-partenariat-entre-ligbmc-satt-conectus-societe-lysogene\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/en\/maladies-rares-signature-dun-partenariat-entre-ligbmc-satt-conectus-societe-lysogene\/\"},\"author\":{\"name\":\"France MANDRY\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/3c07a164c17f01f656480221ba81ab4e\"},\"headline\":\"Maladies rares : signature d&#8217;un partenariat entre l&#8217;IGBMC, la SATT Conectus et la soci\u00e9t\u00e9 Lysogene\",\"datePublished\":\"2018-04-24T09:41:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/en\/maladies-rares-signature-dun-partenariat-entre-ligbmc-satt-conectus-societe-lysogene\/\"},\"wordCount\":408,\"image\":{\"@id\":\"https:\/\/www.satt.fr\/en\/maladies-rares-signature-dun-partenariat-entre-ligbmc-satt-conectus-societe-lysogene\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2018\/04\/cn.jpg\",\"articleSection\":[\"News\",\"Success Stories\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.satt.fr\/en\/maladies-rares-signature-dun-partenariat-entre-ligbmc-satt-conectus-societe-lysogene\/\",\"url\":\"https:\/\/www.satt.fr\/en\/maladies-rares-signature-dun-partenariat-entre-ligbmc-satt-conectus-societe-lysogene\/\",\"name\":\"Maladies rares : signature d'un partenariat entre l'IGBMC, la SATT Conectus et la soci\u00e9t\u00e9 Lysogene - R\u00e9seau SATT\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/en\/maladies-rares-signature-dun-partenariat-entre-ligbmc-satt-conectus-societe-lysogene\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.satt.fr\/en\/maladies-rares-signature-dun-partenariat-entre-ligbmc-satt-conectus-societe-lysogene\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2018\/04\/cn.jpg\",\"datePublished\":\"2018-04-24T09:41:49+00:00\",\"author\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/3c07a164c17f01f656480221ba81ab4e\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.satt.fr\/en\/maladies-rares-signature-dun-partenariat-entre-ligbmc-satt-conectus-societe-lysogene\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.satt.fr\/en\/maladies-rares-signature-dun-partenariat-entre-ligbmc-satt-conectus-societe-lysogene\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.satt.fr\/en\/maladies-rares-signature-dun-partenariat-entre-ligbmc-satt-conectus-societe-lysogene\/#primaryimage\",\"url\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2018\/04\/cn.jpg\",\"contentUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2018\/04\/cn.jpg\",\"width\":6399,\"height\":3569},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.satt.fr\/en\/maladies-rares-signature-dun-partenariat-entre-ligbmc-satt-conectus-societe-lysogene\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.satt.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Maladies rares : signature d&#8217;un partenariat entre l&#8217;IGBMC, la SATT Conectus et la soci\u00e9t\u00e9 Lysogene\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.satt.fr\/en\/#website\",\"url\":\"https:\/\/www.satt.fr\/en\/\",\"name\":\"R\u00e9seau SATT\",\"description\":\"Les Soci\u00e9t\u00e9s d&#039;Acc\u00e9l\u00e9ration du Transfert de Technologies\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.satt.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/3c07a164c17f01f656480221ba81ab4e\",\"name\":\"France MANDRY\",\"url\":\"https:\/\/www.satt.fr\/en\/author\/france\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Maladies rares : signature d'un partenariat entre l'IGBMC, la SATT Conectus et la soci\u00e9t\u00e9 Lysogene - R\u00e9seau SATT","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.satt.fr\/en\/maladies-rares-signature-dun-partenariat-entre-ligbmc-satt-conectus-societe-lysogene\/","twitter_misc":{"Written by":"France MANDRY","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.satt.fr\/en\/maladies-rares-signature-dun-partenariat-entre-ligbmc-satt-conectus-societe-lysogene\/#article","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/maladies-rares-signature-dun-partenariat-entre-ligbmc-satt-conectus-societe-lysogene\/"},"author":{"name":"France MANDRY","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/3c07a164c17f01f656480221ba81ab4e"},"headline":"Maladies rares : signature d&#8217;un partenariat entre l&#8217;IGBMC, la SATT Conectus et la soci\u00e9t\u00e9 Lysogene","datePublished":"2018-04-24T09:41:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.satt.fr\/en\/maladies-rares-signature-dun-partenariat-entre-ligbmc-satt-conectus-societe-lysogene\/"},"wordCount":408,"image":{"@id":"https:\/\/www.satt.fr\/en\/maladies-rares-signature-dun-partenariat-entre-ligbmc-satt-conectus-societe-lysogene\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2018\/04\/cn.jpg","articleSection":["News","Success Stories"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.satt.fr\/en\/maladies-rares-signature-dun-partenariat-entre-ligbmc-satt-conectus-societe-lysogene\/","url":"https:\/\/www.satt.fr\/en\/maladies-rares-signature-dun-partenariat-entre-ligbmc-satt-conectus-societe-lysogene\/","name":"Maladies rares : signature d'un partenariat entre l'IGBMC, la SATT Conectus et la soci\u00e9t\u00e9 Lysogene - R\u00e9seau SATT","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.satt.fr\/en\/maladies-rares-signature-dun-partenariat-entre-ligbmc-satt-conectus-societe-lysogene\/#primaryimage"},"image":{"@id":"https:\/\/www.satt.fr\/en\/maladies-rares-signature-dun-partenariat-entre-ligbmc-satt-conectus-societe-lysogene\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2018\/04\/cn.jpg","datePublished":"2018-04-24T09:41:49+00:00","author":{"@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/3c07a164c17f01f656480221ba81ab4e"},"breadcrumb":{"@id":"https:\/\/www.satt.fr\/en\/maladies-rares-signature-dun-partenariat-entre-ligbmc-satt-conectus-societe-lysogene\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.satt.fr\/en\/maladies-rares-signature-dun-partenariat-entre-ligbmc-satt-conectus-societe-lysogene\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.satt.fr\/en\/maladies-rares-signature-dun-partenariat-entre-ligbmc-satt-conectus-societe-lysogene\/#primaryimage","url":"https:\/\/www.satt.fr\/wp-content\/uploads\/2018\/04\/cn.jpg","contentUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2018\/04\/cn.jpg","width":6399,"height":3569},{"@type":"BreadcrumbList","@id":"https:\/\/www.satt.fr\/en\/maladies-rares-signature-dun-partenariat-entre-ligbmc-satt-conectus-societe-lysogene\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.satt.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Maladies rares : signature d&#8217;un partenariat entre l&#8217;IGBMC, la SATT Conectus et la soci\u00e9t\u00e9 Lysogene"}]},{"@type":"WebSite","@id":"https:\/\/www.satt.fr\/en\/#website","url":"https:\/\/www.satt.fr\/en\/","name":"R\u00e9seau SATT","description":"Les Soci\u00e9t\u00e9s d&#039;Acc\u00e9l\u00e9ration du Transfert de Technologies","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.satt.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/3c07a164c17f01f656480221ba81ab4e","name":"France MANDRY","url":"https:\/\/www.satt.fr\/en\/author\/france\/"}]}},"_links":{"self":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/8945","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/comments?post=8945"}],"version-history":[{"count":0,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/8945\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media\/8944"}],"wp:attachment":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media?parent=8945"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/categories?post=8945"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/tags?post=8945"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}